Preliminary Research On Clinical Value Of Antibodies To Sodium Iodide Symporter In Patients With AITD

Objective: Autoimmune thyroid disease (AITD) is an endocrine disease that includes the various clinical forms of disease, such as Hashimoto's thyroiditis (HT), Graves disease (GD). An important feature of AITD is the production of antibodies to thyroid-specific autoantigens, ie, thyroglobulin (Tg), thyroperoxidase (TPO), and the receptor for thyrotropin (TSHR). Iodine, as an essential component of thyroid hormones,is concentrated by the thyroid gland 20-40 fold with respect to the iodide concentration in plasma. Active iodide uptake across the basolateral membrane of the thyroid follicular cell is mediated by the sodium iodide symporter (NIS). NIS is an intrinsic transmembrane protein that is located in the basolateral membrane of the thyrocyte. Increased NIS mRNA expression has been found in GD, decreased levels of NIS mRNA were observed in HT. It has been reported that the IgGs, purified from sera from patients with Hashimoto's thyroiditis, caused 14 to 62% inhibition of iodide uptake. It is suggested that the antibodies against NIS can interfere the biogenesis of thyroid hormones. The effection of NISAb in AITD was not clear. The aim of our experiments was to investigate the clinical value of antibodies against NIS in patients suffering from HT and GD. Methods:1.Determinations of the optimal reaction condition of ELISA By exploring the various factors of ELISA, the optimal reaction conditions were determined. Including the optimal working concentration and time of enzyme-labeled IgG, the optimal concentration and time of NIS for coating, the optimal reaction time of substrate and serum sample.2. Collection and determination of the sample The patients'serum sample of GD (83 cases) and HT (34 cases) were collected, signs, symptoms, laboratory findings and other examinations were collected. At the same time the level of NISAb, FT3, FT4, TSH was determined. The serum sample and other information of GD were collected when they had been treated after one month, three months and six months. Then determining the level of NISAb, FT3, FT4, TSH.The serum sample of control group as well as laboratory findings, the level of NISAb, FT3, FT4, TSH and other information were collected.3. According to the level of NISAb, the initial patients of GD were divided into two groups: positive or negative, the difference of FT3, FT4, TSH between two sets was compared. The changing rule in treating process of NISAb, FT3, FT4, TSH was observed.4. According to the patients, exophthalmic degree, the patients of GD were divided into two sets which was patients with exophthalmic and patients without exophthalmic, the difference of antibody to NIS,...